痴呆患者的中枢神经系统多重用药
本文基于Optimize整群随机实用试验的二次分析,描述符合CMS Poly-CNS质量指标(中枢神经系统副作用药物多重使用)的痴呆患者及其最常见用药组合。全干预队列中任一时点符合Poly-CNS标准的比例为12.3%,临床医生教育队列为10.8%,干预对符合该标准的 odds 无影响。
要点
- 痴呆患者中约一成符合Poly-CNS标准,应关注其中枢神经系统多重用药风险。
- 最常见组合为阿片类+抗抑郁药+加巴喷丁,提示情绪与疼痛治疗是重点。
- 较年轻、疾病负担更重和女性与符合Poly-CNS标准独立相关。
核心结论
- 认知受限且多病共存、因情绪和/或疼痛症状接受药物治疗的个体可能存在中枢神经系统多重用药风险。
- 干预(患者与临床医生减少处方教育材料)未改变符合Poly-CNS标准的 odds。
研究设计与样本
- Optimize整群随机实用试验的二次分析,研究减少处方教育,实施时间为2019年4月1日至2020年3月31日。
- 两个重叠队列均为服用5种及以上慢性药物的痴呆患者:全干预队列N=2908,临床医生教育队列N=5226。
主要发现
- 全干预队列任一时点符合Poly-CNS标准的比例为12.3%,临床医生教育队列为10.8%。
- 合并全干预队列符合Poly-CNS标准的时间趋势调整P值为.0587,临床医生教育队列为<.0001。
- 两个队列中干预对符合Poly-CNS标准的 odds 均无影响。
- 两个队列中与符合Poly-CNS标准独立相关的特征为较年轻年龄、更大疾病负担和女性;全干预队列中还包括基线时使用临终关怀。
- 最常见的联合用药为阿片类+抗抑郁药+加巴喷丁。
关键数值与推荐
- Poly-CNS质量指标由美国医疗保险和医疗补助服务中心(CMS)制定,用于识别同时使用多种具中枢神经系统副作用药物者。
- 全干预队列任一时点符合Poly-CNS标准的比例为12.3%(N=2908)。
- 临床医生教育队列任一时点符合Poly-CNS标准的比例为10.8%(N=5226)。
- 合并全干预队列时间趋势调整P值为.0587,临床医生教育队列为<.0001。
临床怎么用
- 在痴呆患者中可依据药房发药记录识别符合Poly-CNS标准者,重点审查阿片类、抗抑郁药与加巴喷丁的联合使用。
- 对较年轻、疾病负担重、女性及使用临终关怀的痴呆患者应加强中枢神经系统多重用药评估。
局限性
- 本文为二次分析,原文摘要未报告纳入排除标准、随访时长及混杂因素调整细节。
- 干预未显示效果,原文摘要未报告具体依从性或实施保真度信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Centers for Medicare and Medicaid Services Polypharmacy-CNS (Poly-CNS) quality metric identifies individuals taking multiple medications with central nervous system side effects. The Poly-CNS measure may reduce risky prescribing for persons living with dementia (PLWD). DESIGN: Secondary analysis of the Optimize cluster randomized pragmatic trial of deprescribing education in primary care conducted between April 1, 2019, and March 31, 2020. SETTING AND PARTICIPANTS: Two overlapping cohorts of PLWD taking 5+ chronic medications. The "full intervention" cohort was randomized at the clinic level to receive patient and clinician deprescribing education materials. The "clinician education cohort" included additional individuals whose clinicians received educational materials but who did not receive patient materials. METHODS: Description of individuals meeting Poly-CNS criteria based on pharmacy dispensing records and their highest frequency combinations of medications. Generalized linear mixed models compared the odds of meeting Poly-CNS criteria by intervention or control group and modeled associations between patient characteristics and CNS polypharmacy at any time. Longitudinal analysis using generalized linear mixed models assessed trends of meeting Poly-CNS criteria over time. RESULTS: The proportion meeting Poly-CNS criteria at any time during the observation period in the full intervention cohort (N = 2908) was 12.3% and 10.8% in the clinician education cohort (N = 5226). Adjusted P value for trend over time in the combined full intervention cohort was .0587, and <.0001 in the clinician education cohort. There was no effect of the intervention on odds of meeting Poly-CNS criteria in either cohort. Characteristics in both cohorts independently associated with meeting Poly-CNS criteria were younger age, greater morbidity burden, and female sex plus hospice use at baseline in the full intervention cohort. The most commonly combined medications were opioids plus antidepressants plus gabapentin. CONCLUSIONS AND IMPLICATIONS: Individuals with cognitive limitations and multimorbidity pharmacologically treated for mood and/or pain symptoms may be at risk for CNS polypharmacy.
引用
- Bayliss EA, Powers JD, Weffald LA, et al. Central Nervous System Polypharmacy Among People Living With Dementia. J Am Med Dir Assoc. 2025. PMID: 40460892. doi:10.1016/j.jamda.2025.105708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。